Power and sample size considerations in clinical trials with competing risk endpoints - PubMed (original) (raw)
. 2006 Jul-Sep;5(3):159-71.
doi: 10.1002/pst.200.
Affiliations
- PMID: 17080750
- DOI: 10.1002/pst.200
Power and sample size considerations in clinical trials with competing risk endpoints
Ellen Maki. Pharm Stat. 2006 Jul-Sep.
Abstract
In clinical trials with a time-to-event endpoint, subjects are often at risk for events other than the one of interest. When the occurrence of one type of event precludes observation of any later events or alters the probably of subsequent events, the situation is one of competing risks. During the planning stage of a clinical trial with competing risks, it is important to take all possible events into account. This paper gives expressions for the power and sample size for competing risks based on a flexible parametric Weibull model. Nonuniform accrual to the study is considered and an allocation ratio other than one may be used. Results are also provided for the case where two or more of the competing risks are of primary interest.
Similar articles
- Planning and evaluating clinical trials with composite time-to-first-event endpoints in a competing risk framework.
Rauch G, Beyersmann J. Rauch G, et al. Stat Med. 2013 Sep 20;32(21):3595-608. doi: 10.1002/sim.5798. Epub 2013 Apr 2. Stat Med. 2013. PMID: 23553898 - Competing time-to-event endpoints in cardiology trials: a simulation study to illustrate the importance of an adequate statistical analysis.
Rauch G, Kieser M, Ulrich S, Doherty P, Rauch B, Schneider S, Riemer T, Senges J. Rauch G, et al. Eur J Prev Cardiol. 2014 Jan;21(1):74-80. doi: 10.1177/2047487312460518. Epub 2012 Sep 10. Eur J Prev Cardiol. 2014. PMID: 22964966 - Sample size for a noninferiority clinical trial with time-to-event data in the presence of competing risks.
Han D, Chen Z, Hou Y. Han D, et al. J Biopharm Stat. 2018;28(4):797-807. doi: 10.1080/10543406.2017.1399897. Epub 2017 Nov 20. J Biopharm Stat. 2018. PMID: 29157093 - Post hoc analyses: after the facts.
Srinivas TR, Ho B, Kang J, Kaplan B. Srinivas TR, et al. Transplantation. 2015 Jan;99(1):17-20. doi: 10.1097/TP.0000000000000581. Transplantation. 2015. PMID: 25525920 Review. - Modeling and prediction of subject accrual and event times in clinical trials: a systematic review.
Zhang X, Long Q. Zhang X, et al. Clin Trials. 2012 Dec;9(6):681-8. doi: 10.1177/1740774512447996. Epub 2012 Jun 6. Clin Trials. 2012. PMID: 22674642 Review.
Cited by
- Sample size calculation for the proportional hazards cure model.
Wang S, Zhang J, Lu W. Wang S, et al. Stat Med. 2012 Dec 20;31(29):3959-71. doi: 10.1002/sim.5465. Epub 2012 Jul 11. Stat Med. 2012. PMID: 22786805 Free PMC article. - Competing risk and heterogeneity of treatment effect in clinical trials.
Kent DM, Alsheikh-Ali A, Hayward RA. Kent DM, et al. Trials. 2008 May 22;9:30. doi: 10.1186/1745-6215-9-30. Trials. 2008. PMID: 18498644 Free PMC article. - Competing Risks of Cardiovascular Versus Noncardiovascular Death During Long-Term Follow-Up After Acute Coronary Syndromes.
Fanaroff AC, Roe MT, Clare RM, Lokhnygina Y, Navar AM, Giugliano RP, Wiviott SD, Tershakovec AM, Braunwald E, Blazing MA. Fanaroff AC, et al. J Am Heart Assoc. 2017 Sep 18;6(9):e005840. doi: 10.1161/JAHA.117.005840. J Am Heart Assoc. 2017. PMID: 28923989 Free PMC article. Clinical Trial.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical